SHP-2 phosphatase inhibitor

1. A method of treating leukemia in a subject comprising,

administering to the subject a therapeutically effective amount of a compound having the general formula:

wherein R 17 , R 18 , R 19 , and R 21 can each individually represent a substituent selected from the group consisting of H, F, Cl, Br, I, a lower alkyl group, an alkylene group, an alkenyl group, an alkynyl group, an alkoxy group, an aryl group, an aryloxy group, an alkaryl group, an aralkyl group, O, (CH 2 ) n OR′ (wherein n=1, 2, or 3), CF 3 , CH 2 —CH 2 X, O—CH 2 —CH 2 X, CH 2 —CH 2 —CH 2 X, O—CH 2 —CH 2 X (wherein X═F, Cl, Br, or I), CN, C═O, (C═O)—R′, N(R′) 2 , NO 2 , (C═O)N(R′) 2 , O(CO)R′, OR′, SR′, COOR′, R ph , CR′═CR′—R ph , CR 2 ′—CR 2 ′—R ph (wherein R ph represents an unsubstituted or substituted phenyl group and R′ represents hydrogen, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, an alkaryl group, an aralkyl group, an alkyloxy group, a cyano, or an isocyano group), and a pharmaceutically acceptable salt thereof, the leukemia characterized by an SHP-2 activating E76K mutation.

2. The composition of claim 1 , wherein R 17 , R 18 , and R 19 , can each represent H or a lower alkyl group and R 21 is selected from the group consisting of H, F, Cl, Br, I, a lower alkyl group, an alkylene group, an alkenyl group, an alkynyl group, an alkoxy group, an aryl group, an aryloxy group, an alkaryl group, and an aralkyl group.

3. The method of claim 1 , the compound being selected from the group consisting of:

and a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , the compound having following formula:

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the leukemia is juvenile myelomonocytic leukemia (JMML).